ethyl 2-amino-5-benzyl-6-chloro-4-methylnicotinate | 1413280-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 2-amino-5-benzyl-6-chloro-4-methylnicotinate
• 英文别名: Ethyl 2-amino-5-benzyl-6-chloro-4-methylpyridine-3-carboxylate；ethyl 2-amino-5-benzyl-6-chloro-4-methylpyridine-3-carboxylate
• CAS: 1413280-93-9
• 化学式: C₁₆H₁₇ClN₂O₂
• 分子量: 304.776
• InChiKey: ITDOMKJYCXQZQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-amino-5-benzyl-6-chloro-4-methylnicotinate 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成
  参考文献：
  名称：

  Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity

  摘要：

  A series of 2-amino-[1,8]-naphthyridine-3-carboxamides (ANCs) with potent inhibition of bacterial NAD+-dependent DNA ligases (LigAs) evolved from a 2,4-diaminopteridine derivative discovered by HTS. The design was guided by several highly resolved X-ray structures of our inhibitors in complex with either Streptococcus pneumoniae or Escherichia coli LigA. The structure-activity-relationship based on the ANC scaffold is discussed. The in-depth characterization of 2-amino-6-bromo-7-(trifluoromethyl)-[1,8]-naphthyridine-3-carboxamide, which displayed promising in vitro (MIC Staphylococcus aureus 1 mg/L) and in vivo anti-staphylococcal activity, is presented. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.094
• 作为产物：
  描述：

  2-苄基乙酰乙酸乙酯 在 吡啶 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 生成 ethyl 2-amino-5-benzyl-6-chloro-4-methylnicotinate
  参考文献：
  名称：

  Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity

  摘要：

  A series of 2-amino-[1,8]-naphthyridine-3-carboxamides (ANCs) with potent inhibition of bacterial NAD+-dependent DNA ligases (LigAs) evolved from a 2,4-diaminopteridine derivative discovered by HTS. The design was guided by several highly resolved X-ray structures of our inhibitors in complex with either Streptococcus pneumoniae or Escherichia coli LigA. The structure-activity-relationship based on the ANC scaffold is discussed. The in-depth characterization of 2-amino-6-bromo-7-(trifluoromethyl)-[1,8]-naphthyridine-3-carboxamide, which displayed promising in vitro (MIC Staphylococcus aureus 1 mg/L) and in vivo anti-staphylococcal activity, is presented. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.094

文献信息

• [EN] 2 -AMINO- 1, 8 -NAPHTHYRIDINE-3 -CARBOXAMIDE DERIVATIVES AS ANTIMICROBIAL AGENTS<br/>[FR] DÉRIVÉS DE 2-AMINO-1,8-NAPHTYRIDINE-3-CARBOXAMIDE UTILISÉS COMME AGENTS ANTIMICROBIENS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013072882A1

  公开（公告）日：2013-05-23

  The present invention concerns novel 2-amino-1,8-naphthyridine-3-carboxamide derivatives of formula I, a pharmaceutical antibacterial composition containing them and the use of these compounds in the manufacture of a medicament for the treatment of infections (e.g. bacterial infections). These compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including among others Gram-positive and Gram-negative aerobic and anaerobic bacteria.

  本发明涉及公式I的新型2-氨基-1,8-萘啶-3-甲酰胺衍生物，包含它们的药用抗菌组合物以及利用这些化合物制造用于治疗感染（例如细菌感染）的药物。这些化合物是有用的抗微生物药剂，对包括革兰氏阳性和阴性需氧菌和厌氧菌在内的各种人类和兽医病原体具有有效作用。
• Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity
  作者：Jean-Philippe Surivet、Roland Lange、Christian Hubschwerlen、Wolfgang Keck、Jean-Luc Specklin、Daniel Ritz、Daniel Bur、Hans Locher、Peter Seiler、Daniel Stefan Strasser、Lars Prade、Christopher Kohl、Christine Schmitt、Gaëlle Chapoux、Eser Ilhan、Nadia Ekambaram、Alcibiade Athanasiou、Andreja Knezevic、Daniela Sabato、Alain Chambovey、Mika Gaertner、Michel Enderlin、Maria Boehme、Virginie Sippel、Pierre Wyss

  DOI：10.1016/j.bmcl.2012.08.094

  日期：2012.11

  A series of 2-amino-[1,8]-naphthyridine-3-carboxamides (ANCs) with potent inhibition of bacterial NAD+-dependent DNA ligases (LigAs) evolved from a 2,4-diaminopteridine derivative discovered by HTS. The design was guided by several highly resolved X-ray structures of our inhibitors in complex with either Streptococcus pneumoniae or Escherichia coli LigA. The structure-activity-relationship based on the ANC scaffold is discussed. The in-depth characterization of 2-amino-6-bromo-7-(trifluoromethyl)-[1,8]-naphthyridine-3-carboxamide, which displayed promising in vitro (MIC Staphylococcus aureus 1 mg/L) and in vivo anti-staphylococcal activity, is presented. (C) 2012 Elsevier Ltd. All rights reserved.